Alimera Sciences, Inc. (NASDAQ:ALIM) is set to announce third quarter earning results on Wednesday 28th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ALIM to report 3Q20 loss of $ 0.44 per share.
For the full year, analysts anticipate top line of $ 49.52 million, while looking forward to loss of $ 1.15 per share bottom line.
Previous Quarter Performance
Alimera Sciences, Inc. posted loss for the second quarter of $ 0.51 per share, from the revenue of $ 10.04 million. The consensus estimates are loss of $ 1.44 per share from $ 6.94 million in revenue. The bottom line results beat street analysts by $ 0.93 or 64.58 percent, at the same time, top line results outshined analysts by $ 3.10 million or 44.67 percent.
Stock Performance
Shares of Alimera Sciences, Inc. traded low $ -0.09 or -2.04 percent on Tuesday, reaching $ 4.32 with volume of 15.40 thousand shares. Alimera Sciences, Inc. has traded high as $ 4.42 and has cracked $ 4.30 on the downward trend
According to the previous trading day, closing price of $ 4.32, representing a 54.20 % increase from the 52 week low of $ 2.86 and a 55.81 % decrease over the 52 week high of $ 9.98.
The company has a market capital of $ 21.74 million and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
